Shares of several COVID-19 vaccine developers sank fast enough to reflect investor jitters about vaccine policy given RFK’s ...

The selection of vaccine sceptic Robert F Kennedy Jr by US President-elect Donald Trump to head the Department of Health and ...

Although it is seeing a downturn in sales and profits, German biotech BioNTech (Nasdaq: BNTX) is continuing to acquire assets ...

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

Arcturus Therapeutics (ARCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

One stock yields 6% today. Another has grown its dividend by 460% over the past decade. Both are blue chip bargains to buy ...

Revenue from Comirnaty, its COVID vaccine, has fallen by 66% this year. But in specialty care, revenue has risen by 11%, and ...

Raining on the parade even more, Pfizer just reported some good news that seems to confirm the presence of some internal issues. So let's examine this new green flag that's also a red flag for anyone ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

On Oct. 29, Pfizer PFE announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on ...

Schools closed. Hospitals overflowed. Around the world, millions died. For Pfizer, the success of its Comirnaty vaccine and its antiviral drug Paxlovid couldn’t have come at a better time.